The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m(2).

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Dulaglutide 1.5 mg once weekly is a novel glucagon-like peptide 1 (GLP-1) receptor agonist, for the treatment of type two diabetes mellitus (T2DM). The objective was to estimate the cost-effectiveness of dulaglutide once weekly vs liraglutide 1.8 mg once daily for the treatment of T2DM in Spain in patients with a BMI ≥30 kg/m(2).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Med Econ

Title: Journal of medical economics

Publisher: Informa UK Limited

ISSN (Electronic): 1941-837X

ISSN (Print): 1369-6998

Publication date (Electronic): May 2017

Volume: 20

Issue: 5

Affiliations

[1 ] a Eli Lilly S.A. , Madrid , Spain.

[2 ] b IMS Health , London , UK.

[3 ] c Eli Lilly Finland , Helsinki , Finland.

Article

DOI: 10.1080/13696998.2016.1275651

PubMed ID: 28008768

SO-VID: 215f4d30-d8bc-4321-84a5-00206be92385

History

Keywords: Diabetes,Spain,cost-effectiveness,dulaglutide,liraglutide,type 2 diabetes

Data availability:

Keywords: Diabetes, Spain, cost-effectiveness, dulaglutide, liraglutide, type 2 diabetes

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 7

See all cited by

The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m(2).

Read this article at